119 related articles for article (PubMed ID: 10738905)
1. Magnetic field induced inhibition of human osteosarcoma cells treated with adriamycin.
Chakkalakal DA; Mollner TJ; Bogard MR; Fritz ED; Novak JR; McGuire MH
Cancer Biochem Biophys; 1999 Jul; 17(1-2):89-98. PubMed ID: 10738905
[TBL] [Abstract][Full Text] [Related]
2. Hydrogen peroxide overload increases adriamycin-induced apoptosis of SaOS(2)FM, a manganese superoxide dismutase-overexpressing human osteosarcoma cell line.
Wang Y; Kuroda M; Gao XS; Asaumi J; Shibuya K; Kawasaki S; Akaki S; St Clair D; Hiraki Y; Kanazawa S
Int J Oncol; 2005 May; 26(5):1291-300. PubMed ID: 15809720
[TBL] [Abstract][Full Text] [Related]
3. Antiproliferative and antimigratory effects of doxorubicin in human osteosarcoma cells exposed to extracellular matrix.
Harisi R; Dudás J; Tímár F; Pogány G; Paku S; Tímár J; Kovalszky I; Szendroi M; Jeney A
Anticancer Res; 2005; 25(2A):805-13. PubMed ID: 15868912
[TBL] [Abstract][Full Text] [Related]
4. Drug resistance modification using pulsing electromagnetic field stimulation for multidrug resistant mouse osteosarcoma cell line.
Hirata M; Kusuzaki K; Takeshita H; Hashiguchi S; Hirasawa Y; Ashihara T
Anticancer Res; 2001; 21(1A):317-20. PubMed ID: 11299755
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of a nitrogen-containing bisphosphonate, minodronate, in conjunction with a p38 mitogen activated protein kinase inhibitor or doxorubicin against malignant bone tumor cells.
Kubo T; Shimose S; Matsuo T; Sakai A; Ochi M
Cancer Chemother Pharmacol; 2008 Jun; 62(1):111-6. PubMed ID: 17874104
[TBL] [Abstract][Full Text] [Related]
6. Pulsed Electromagnetic Field Stimulation Promotes Anti-cell Proliferative Activity in Doxorubicin-treated Mouse Osteosarcoma Cells.
Muramatsu Y; Matsui T; Deie M; Sato K
In Vivo; 2017 Jan; 31(1):61-68. PubMed ID: 28064222
[TBL] [Abstract][Full Text] [Related]
7. Anticancer agents sensitize osteosarcoma cells to TNF-related apoptosis-inducing ligand downmodulating IAP family proteins.
Mirandola P; Sponzilli I; Gobbi G; Marmiroli S; Rinaldi L; Binazzi R; Piccari GG; Ramazzotti G; Gaboardi GC; Cocco L; Vitale M
Int J Oncol; 2006 Jan; 28(1):127-33. PubMed ID: 16327988
[TBL] [Abstract][Full Text] [Related]
8. Platinum agents in the treatment of osteosarcoma: efficacy of cisplatin vs. carboplatin in human osteosarcoma cell lines.
Robson H; Meyer S; Shalet SM; Anderson E; Roberts S; Eden OB
Med Pediatr Oncol; 2002 Dec; 39(6):573-80. PubMed ID: 12376980
[TBL] [Abstract][Full Text] [Related]
9. IGF1R-targeted therapy and its enhancement of doxorubicin chemosensitivity in human osteosarcoma cell lines.
Luk F; Yu Y; Walsh WR; Yang JL
Cancer Invest; 2011 Oct; 29(8):521-32. PubMed ID: 21843050
[TBL] [Abstract][Full Text] [Related]
10. [In vitro experimental study of adriamycin-loaded chitosan drug delivery system].
Zhang Y; Hou C; Chen A
Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi; 1997 Sep; 11(5):309-11. PubMed ID: 9867937
[TBL] [Abstract][Full Text] [Related]
11. Intraarterial Cisplatin and intravenous adriamycin in nonmetastatic osteosarcoma of the extremities: a single institution experience in Taiwan.
Chiu TJ; Wang JW; Chen YJ; Tang Y; Huang CH
Chang Gung Med J; 2009; 32(1):72-80. PubMed ID: 19292942
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of cytotoxic treatment of patients with osteosarcoma by an in vitro chemoresistance assay.
Agiostratidou G; Demertzis N; Gonos ES
Anticancer Res; 2000; 20(5B):3603-8. PubMed ID: 11131668
[TBL] [Abstract][Full Text] [Related]
13. Kinetic effects of adriamycin and bleomycin on two osteosarcoma models.
Bell DF; Bell RS; Mankin HJ; Gebhardt MC; Weltie F; O'Brien T
J Orthop Res; 1988; 6(1):51-7. PubMed ID: 2445944
[TBL] [Abstract][Full Text] [Related]
14. 4-Demethoxy-3'-deamino-3'-aziridinyl-4'-methylsulphonyl-daunorubicin (PNU-159548): a promising new candidate for chemotherapeutic treatment of osteosarcoma patients.
Pasello M; Hattinger CM; Stoico G; Manara MC; Benini S; Geroni C; Mercuri M; Scotlandi K; Picci P; Serra M
Eur J Cancer; 2005 Sep; 41(14):2184-95. PubMed ID: 16140527
[TBL] [Abstract][Full Text] [Related]
15. Targeted adriamycin delivery to MXT-B2 metastatic mammary carcinoma cells by transferrin liposomes: effect of adriamycin ADR-to-lipid ratio.
Lopez-Barcons LA; Polo D; Llorens A; Reig F; Fabra A
Oncol Rep; 2005 Nov; 14(5):1337-43. PubMed ID: 16211306
[TBL] [Abstract][Full Text] [Related]
16. Combined anti-fetal liver kinase 1 monoclonal antibody and continuous low-dose doxorubicin inhibits angiogenesis and growth of human soft tissue sarcoma xenografts by induction of endothelial cell apoptosis.
Zhang L; Yu D; Hicklin DJ; Hannay JA; Ellis LM; Pollock RE
Cancer Res; 2002 Apr; 62(7):2034-42. PubMed ID: 11929822
[TBL] [Abstract][Full Text] [Related]
17. Syndecan-2 affects the basal and chemotherapy-induced apoptosis in osteosarcoma.
Orosco A; Fromigué O; Bazille C; Entz-Werle N; Levillain P; Marie PJ; Modrowski D
Cancer Res; 2007 Apr; 67(8):3708-15. PubMed ID: 17440083
[TBL] [Abstract][Full Text] [Related]
18. Neoadjuvant chemotherapy with high-dose Ifosfamide, high-dose methotrexate, cisplatin, and doxorubicin for patients with localized osteosarcoma of the extremity: a joint study by the Italian and Scandinavian Sarcoma Groups.
Ferrari S; Smeland S; Mercuri M; Bertoni F; Longhi A; Ruggieri P; Alvegard TA; Picci P; Capanna R; Bernini G; Müller C; Tienghi A; Wiebe T; Comandone A; Böhling T; Del Prever AB; Brosjö O; Bacci G; Saeter G;
J Clin Oncol; 2005 Dec; 23(34):8845-52. PubMed ID: 16246977
[TBL] [Abstract][Full Text] [Related]
19. Interferon-alpha enhances sensitivity of human osteosarcoma U2OS cells to doxorubicin by p53-dependent apoptosis.
Yuan XW; Zhu XF; Huang XF; Sheng PY; He AS; Yang ZB; Deng R; Feng GK; Liao WM
Acta Pharmacol Sin; 2007 Nov; 28(11):1835-41. PubMed ID: 17959036
[TBL] [Abstract][Full Text] [Related]
20. Dose intensity of chemotherapy for osteosarcoma and outcome in the Cooperative Osteosarcoma Study Group (COSS) trials.
Eselgrim M; Grunert H; Kühne T; Zoubek A; Kevric M; Bürger H; Jürgens H; Mayer-Steinacker R; Gosheger G; Bielack SS
Pediatr Blood Cancer; 2006 Jul; 47(1):42-50. PubMed ID: 16206218
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
